The analysis, covering clinical trials from 2002 to 2024, compared pro-angiogenic interventions against placebos across a diverse patient cohort. Results showed malignancy incidence rates of 0.84 per 100 patient-years for the treatment group, compared to 0.72 for those receiving placebos—both figures falling below the 1.0 benchmark for age-matched populations. Retinal complications were similarly rare, effectively neutralizing fears that stimulating blood vessel growth might trigger unintended pathological side effects.
In section Releases
Isomab Study Clears Path for Angiogenic Heart Disease Treatments
A two-decade systematic review has dismantled long-standing safety concerns regarding pro-angiogenic heart therapies, revealing no increased risk of cancer or retinopathy. By analyzing data from 636 patients, the Nottingham-based firm Isomab aims to clear the clinical bottleneck that has historically hindered the development of vessel-growth treatments for coronary artery disease.
This evidence provides a regulatory tailwind for Isomab’s lead candidate, ISM-001. Unlike traditional growth factor therapies that forcefully stimulate vessel production, ISM-001 functions as an antibody designed to neutralize VEGF-A165b, a protein that acts as an overactive brake on the body’s natural angiogenic processes. Chief Scientific Officer Professor David Bates described the findings as a foundation for upcoming first-in-human trials, which will target patients suffering from chronic, treatment-refractory angina. CEO Dr. Philip Brainin emphasized that the objective remains to rebalance VEGF-A signaling, allowing the heart to leverage its own capacity for self-repair rather than relying on blunt stimulation.
Comments (0)
No comments yet. Be the first!